AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00561379 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CEEP-RITUXIMAB
Description: High dose chemotherapy with rituximab including autologous stem cell support.
Study NCT01064726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen
Description: 800 mg oral
Study NCT01064726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate
Description: 200 mcg intra-nasal
Study NCT01064726 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00726583 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PX-866
Description: Oral solution, dose escalation, once per day on days 1 to 5 and 8 to 12 or days 1-28 of a 28 day cycle, until progression or development of unacceptable toxicity
Study NCT01174563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib [Tarceva]
Description: 150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol
Study NCT05671666 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Urea cycle flux study
Description: Quantification of ureagenesis
Study NCT03100279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Cat/CAT Project
Description: The Coping Cat program, developed by Kendall and colleagues (Kendall, 1994; Kendall, 2000; Kendall, Kane, Howard, \& Siqueland, 1989; Kendall, Flannery-Schroeder et al., 1997), involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward. The therapist uses modeling (e.g., revealing therapist's own anxiety and sharing successful coping experiences), in vivo exposure tasks, role-playing (e.g., to prepare for exposure tasks), relaxation training, and contingent reinforcement (e.g., for trying and for succeeding at exposure tasks), in developing these four themes.
Study NCT03100279 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary and Secondary Coping Enhancement Therapy
Description: PASCET is a brief (11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, \& Snyder, 1982; Weisz et al., 1984a,b). In this model, primary control involves efforts to cope by making objective conditions (e.g., one's activities, one's peer status) conform to one's wishes. In contrast, secondary control involves coping by adjusting oneself (e.g., one's expectations, interpretations) to fit objective conditions, so as to influence their subjective impact without altering the actual conditions. The goal is for youngsters to build their skills in primary and secondary control coping, and apply those skills to events and conditions that can trigger depression. Therapists are guided by a Therapist's Manual and use a youth workbook.
Study NCT02124408 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Behavioral Intervention
Study NCT01508767 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Removal of urethral catheter
Description: All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior to undergoing colorectal resection. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 48 hours following surgery. Participants assigned to the control group will have their urethral catheters removed within 12 hours of withdrawal of the epidural infusion, as is standard practice in our institution.
Study NCT01508767 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Removal of urethral catheter
Description: All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior to undergoing colorectal resection. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 48 hours following surgery. Participants assigned to the control group will have their urethral catheters removed within 12 hours of withdrawal of the epidural infusion, as is standard practice in our institution.
Study NCT02038036 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Available Therapy
Description: Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib.
Study NCT02038036 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Ruxolitinib was administered at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid.
Study NCT02946697 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support intervention
Description: The social support intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
Study NCT04174586 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: microtransplantation
Description: HLA mismatched donor cord blood infusion
Study NCT04316143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral zamicastat
Description: Tablets for oral administration under fed conditions containing 100 mg of zamicastat
Study NCT04171960 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood draw
Description: Venous whole blood collection within 12 hours and 12-24 hours following injury.
Study NCT00197015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VARIVAX®
Description: 1 dose administered subcutaneously
Study NCT00197015 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: VARIVAX®
Description: 1 dose administered subcutaneously
Study NCT00988286 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CEP, MEP, TMS
Description: Patients and healthy volunteers will undergo cortical evoked potentials (CEP), motor evoked potentials (MEP) and transcranial evoked potentials (TMS).
Study NCT04171960 — intervention group
Intervention type: OTHER
Intervention: Outcome assessments
Description: Administered at baseline.
Study NCT04628585 — intervention group
Intervention type: OTHER
Intervention: Safety and efficacy assessments
Description: Safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant
Study NCT02298530 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of caffeine and theanine
Description: Beverage containing caffeine and theanine
Study NCT02298530 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Caffeine
Description: Beverage containing caffeine
Study NCT05491720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RisperiDONE 1 MG/ML
Description: Patients will receive two daily Risperidone 1 mg tablets (Sobhan Pharmaceutical Company) for 10 consecutive days
Study NCT02215772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370 BS
Study NCT01497119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979, 300 mg
Description: Type=exact number, unit=mg, number=300, form=tablet, route=oral use, once daily for 6 weeks.
Study NCT01497119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-39758979, 100 mg
Description: Type=exact number, unit=mg, number=100, form=tablet, route=oral use, once daily for 6 weeks.
Study NCT01497119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Form=tablet, route=oral use, once daily for 6 weeks.
Study NCT00625924 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States - Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
Study NCT00625924 — intervention group
Intervention type: BEHAVIORAL
Intervention: questionnaires
Description: Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
Study NCT03514186 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Speech and Language Therapy
Description: Includes:~* one hour of individual therapy using a multimodality treatment called Verb Network Strengthening Treatment (VNeST) that simultaneously targets semantics (word retrieval) and syntax (sentence construction);~* one hour of constraint induced language therapy (CILT) where participants are paired and practice requesting and providing specific information using only spoken language;~* one hour in the computer lab working on programs called Oral Reading for Language in Aphasia (ORLA) and AphasiaScripts; and~* one hour in a conversation group that emphasizes multimodality communication
Study NCT03514186 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Speech and Language Therapy
Description: Includes:~* one hour of individual therapy using a multimodality treatment called Verb Network Strengthening Treatment (VNeST) that simultaneously targets semantics (word retrieval) and syntax (sentence construction);~* one hour of constraint induced language therapy (CILT) where participants are paired and practice requesting and providing specific information using only spoken language;~* one hour in the computer lab working on programs called Oral Reading for Language in Aphasia (ORLA) and AphasiaScripts; and~* one hour in a conversation group that emphasizes multimodality communication
Study NCT03806335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Infiltration
Description: The infiltration will be performed by the anesthetist using a 25G- 3.5cm curved needle. A total of 2.5 ml of local anesthetic mixture will be used for each tonsil. The mixture will contain: 10 ml xylocaine 2% an d10 ml bupivacaine 0.5%
Study NCT03806335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive 2.5 ml normal saline in each tonsil
Study NCT03806335 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: General anesthesia
Description: All patients will receive general anesthesia prior to infiltration
Study NCT03806335 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: General anesthesia
Description: All patients will receive general anesthesia prior to infiltration
Study NCT02249117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIWH 3
Study NCT02249117 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04429841 — intervention group
Intervention type: PROCEDURE
Intervention: Radical gastrectomy with D1 lymphadenectomy
Study NCT04429841 — intervention group
Intervention type: PROCEDURE
Intervention: Radical gastrectomy with D2 lymphadenectomy
Study NCT01657526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)
Description: Administered intramuscularly (IM) in the deltoid region of non-dominant arm
Study NCT01657526 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)
Description: 2 doses administered IM in the deltoid region of non-dominant arm
Study NCT01657526 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Saline placebo
Description: 2 doses administered IM in the deltoid region of non-dominant arm
Study NCT05491720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: Patients will receive 10 sessions of 20 minutes of 1.5 mA electrical stimulation on consecutive days
Study NCT05491720 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo tablet (Galenus pharmaceutical company)
Study NCT03141684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Given IV
Study NCT03141684 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV
Study NCT03141684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood and urine
Study NCT03141684 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT
Study NCT05491720 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Patients will receive placebo tablet (Galenus pharmaceutical company)
Study NCT05491720 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: sham transcranial direct current stimulation
Description: Patients will receive 10 sessions of 20 minutes of sham electrical stimulation on consecutive days
Study NCT05491720 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham transcranial direct current stimulation
Description: Patients will receive 10 sessions of 20 minutes of sham electrical stimulation on consecutive days
Study NCT00981201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Months 1-3:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)
Study NCT00981201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)
Study NCT00981201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Months 4-6:~As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)
Study NCT00981201 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Months 1-3:~By mouth twice daily.
Study NCT00981201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Months 1-3:~By mouth twice daily.
Study NCT00981201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Months 4-6:~By mouth twice daily.
Study NCT00981201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Months 4-6:~By mouth twice daily.
Study NCT04282642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Training
Description: Participants (n=20) provided game console with cognitive training games and activities.
Study NCT04282642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WLC (Waitlist Control)
Description: Participants (n=20) will receive the cognitive training intervention later, following week 8 assessments.
Study NCT02758769 — intervention group
Intervention type: BIOLOGICAL
Intervention: ORENCIA Subcutaneous Injection
Study NCT03802396 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CN-105
Description: Three doses of CN-105 will be used in three successive cohorts of 50 patients each.~0.1 mg/kg (cohort 1), 0.5 mg/kg (cohort 2), 1 mg/kg (cohort 3)~The study drug will be administered by IV every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses.
Study NCT03802396 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive placebo intravenously every 6 hours, beginning 1 hour prior to surgery, until postoperative day 3 or hospital discharge, whichever occurs first, up to a maximum of 13 doses, identical to those receiving the study drug.
Study NCT06750770 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: KDIGO CRITERIA
Description: 2012 KDIGO DIAGNOSTIC CRITERIA
Study NCT00543127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: 500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral Anastrozole per day during 5 years.
Study NCT00543127 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anastrozole
Description: 1 mg oral Anastrozole per day during 5 years.
Study NCT00543127 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anastrozole
Description: 1 mg oral Anastrozole per day during 5 years.
Study NCT02618941 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AFFITOPE® PD01A
Description: s.c. injection
Study NCT00226356 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Supplements of L-methionine, betaine and folate
Study NCT00163293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide
Description: Ciclesonide metered-dose inhaler
Study NCT01199965 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MAP0004
Description: 1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
Study NCT00163293 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ciclesonide placebo-matching metered-dose inhaler
Study NCT03834740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Ribociclib administered orally in 5 daily doses prior to resection
Study NCT03834740 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: Everolimus administered orally in 5 daily doses prior to resection
Study NCT01107886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Saxagliptin
Description: 5 mg or 2.5 mg once daily
Study NCT01107886 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03506360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study NCT03506360 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT03506360 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03506360 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01580787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Balance Training with Nintendo Wii Fit
Description: The participants of the study trained 10 balance games during 14 sessions.
Study NCT01580787 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy
Description: Patients of the control group was trained with balance exercises.
Study NCT03253172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Chloride
Description: Two potassium supplements with varying anions.
Study NCT03253172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Potassium Citrate
Description: Potassium Citrate
Study NCT03253172 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01199965 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: IV DHE
Description: IV DHE administered at Visit 2 or 3 as per protocol
Study NCT04360941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Highly selective oral inhibitor of CDK4 and CDK6.
Study NCT04360941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Fully human IgG1 monoclonal antibody (mAb) binds to the PD-L1 cell surface ligand and blocks its interaction with the PD-1 cell surface receptor.
Study NCT02242266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium low dose
Description: inhalation powder, hard PE capsule
Study NCT02242266 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium medium dose
Description: inhalation powder, hard PE capsule
Study NCT02242266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spiriva® HandiHaler® high dose
Description: Tiotropium inhalation powder, hard gelatine capsule
Study NCT02242266 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo via the blue HandiHaler®
Description: oral inhalation via the blue HandiHaler®
Study NCT02242266 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo via the blue HandiHaler®
Description: oral inhalation via the blue HandiHaler®